| Momelotinib in VEXAS Syndrome (NCT07098936) | Groupe Francophone des Myelodysplasies | 2025-11-25 |
| Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) (NCT06670222) | Groupe Francophone des Myelodysplasies | 2025-07-22 |
| Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes (NCT05782127) | Groupe Francophone des Myelodysplasies | 2023-12-06 |
| Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (NCT05768711) | Groupe Francophone des Myelodysplasies | 2023-10-04 |
| Venetoclax in Patients With MDS or AML in Relapse After AHSCT (NCT05226455) | Groupe Francophone des Myelodysplasies | 2022-11-23 |
| Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA (NCT05181735) | Groupe Francophone des Myelodysplasies | 2022-05-18 |
| BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS (NCT04827719) | Groupe Francophone des Myelodysplasies | 2021-05-01 |
| CPX-351 in Higher Risk Myelodysplastic Syndromes (NCT04273802) | Groupe Francophone des Myelodysplasies | 2020-04-29 |
| IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome (NCT03503409) | Groupe Francophone des Myelodysplasies | 2019-05-14 |
| IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome (NCT03744390) | Groupe Francophone des Myelodysplasies | 2019-04-02 |
| Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine (NCT03588078) | Groupe Francophone des Myelodysplasies | 2018-09-15 |